File(s) under permanent embargo
Challenges and opportunities for siRNA-based cancer treatment
journal contributionposted on 2017-02-28, 00:00 authored by Tao Wang, Sarah ShigdarSarah Shigdar, Hadi Al Shamaileh, M P Gantier, Wang Yin, Dongxi Xiang, L Wang, S-F Zhou, Y Hou, P Wang, W Zhang, C Pu, Wei DuanWei Duan
As one of the life-threatening diseases involving multi-step genetic and epigenetic disorders, cancer has long been a dynamic research area for siRNA-based therapy as half of the current siRNA-based clinical trials are involved in oncology. However, despite consistent enthusiasm in the academic world, siRNA-based cancer treatment still faces obstacles and difficulties in clinical development. In this article, we discuss key challenges facing siRNA-based cancer treatment revealed from recent clinical and preclinical studies, including chemical modification, tumour penetration, endosomal escape, target selection and off-target effects. In addition, opportunities and avenues for translating siRNA technology from bench to oncologic clinics are explored.